A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, up to Placebo- Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment with RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2018
This article has no abstract
Epistemonikos ID: e7aed698cb8030fb988e0c375281fc5e0bf6597c
First added on: Apr 11, 2025